P.U.L.S. (Partners for Development Investments in Life Sciences) is a unique life science development company. P.U.L.S. invests in early projects and actively develops them in close collaboration with the innovators, all the way from idea to projects attractive for the industry.
The company was founded in 2002 and this far P.U.L.S. has started nine project companies since 2003, exited three, of which one (LIDDS) has been listed on the Nasdaq OMX Firth North Stock Exchange. P.U.L.S.’ current projects are: AcuCort, Adenovir Pharma, Glactone Pharma, Laccure och Oncorena.
P.U.L.S. consists of an operational management team as well as around 40 partners with vast experience in life science and expertise throughout the entire value chain, from R&D to commercialization. P.U.L.S.'s board evaluates new projects in collaboration with its partners and external experts. After securing capital, they then work jointly with the portfolio companies throughout the entire development process until exit.
P.U.L.S. has its headquarters in Helsingborg, Sweden.